NeuroSense Therapeutics Ltd. Restricted Cash and Cash Equivalents
NeuroSense Therapeutics Ltd. (NRSN) had Restricted Cash and Cash Equivalents of $6.00 million as of 2022-12-31, per its 6-K filed 2024-06-17.
Discontinued › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2024-06-17
- 2022-12-31: Restricted Cash and Cash Equivalents $6.00M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2022-12-31 | $6.00M 6-K · filed 2024-06-17 |